Patients with chemorefractory metastatic colorectal cancer derive no overall survival benefit from giving anti-EGFR ...

Among 16 patients with this difficult-to-treat tumor "with few treatment options," the confirmed overall response rate (ORR) ...

President Donald Trump on Friday announced a deal with pharmaceutical company Merck and its U.S. subsidiary, EMD Serono, to ...

Government agreement with IVF drug manufacturer drops price in exchange for tariff reductions, expedited FDA approval ...

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

As a newly christened manufacturing facility comes online in one part of Ireland, Merck KGaA plans to turn out the lights at ...

Trump, in an effort to lower drug costs for U.S. patients who pay far more than in other wealthy nations, has so far struck ...

EMD Serono also entered an agreement with the U.S. Secretary of Commerce to exclude its pharmaceutical products and ...

President Donald Trump announced a new agreement aimed at significantly lowering the cost of fertility treatments for ...

Tarlatamab combined with chemoimmunotherapy achieved a 71% objective response rate in ES-SCLC, with a median response duration of 11 months. The safety profile was manageable, with grade 3 or 4 ...

Although desmoid tumors do not metastasize, they can be associated with recurrence rates of up to 77% after surgical ...